2024-02-06T12:31:23-08:00 2023-12-31 271661785 CMRosen LLC 17440 Dallas Pkwy Ste 218 Dallas TX 75287 990 2023-01-01 820864340 Cure RTD Foundation CURE 9728610415 PO Box 1228 Red Oak TX 75154 Carly Gilbert VP / Treasurer 2024-02-06 true Carly Gilbert 999009999 true Chad M Rosen CPA P01071321 9728181400 2 AAL1 IAL1 FAL1 2023 2023-04-26 12:10:37Z Chad Griffith PO Box 1228 Red Oak TX 75154 380539 false X curertd.org X 2017 TX To encourage, guide, and fund additional research to improve understanding, diagnosis, and treatment of Riboflavin Transporter Deficiency ("RTD"). 4 3 1 10 0 378086 380248 0 0 378 291 378464 380539 58521 225271 0 12298 16568 0 4701 3867 16299 74686 258138 303778 122401 975125 1097526 0 975125 1097526 To encourage, guide, and fund additional research to improve understanding, diagnosis, and treatment of Riboflavin Transporter Deficiency ("RTD"). false false 236719 225271 Cure RTD Foundation is proud to have funded the four following research projects in advancement of the understanding and treatment of RTD: (a) $120,000 into a 2-year project aimed to gain further insights into the structure/function relationships ensuring the correct functioning of RFVT2, whose perturbations are at the bases of a severe neurodegenerative disorder, namely RTD Type 2 (OMIM # 614707); (b) $18,685 to investigate the role of the blood brain barrier in Riboflavin transport in patients with RTD; (c) $51,990 into a 2-year project to begin understanding the eye defects of RTD patients by developing iPSC-derived Retinal Organoids: a 3D model to test the efficacy of the AAV Gene Therapy; and (d) $34,596 to cover costs to set up, optimize, and run flavin testing on 222 mouse brain and blood samples. 236719 true true false false false false false false false false false false false false false false false false false false true true false false false false false true false false false false false false false false false false false false false false false false false false false true 0 0 false 1 true false false false false false false false 0 false false false false false false false X 4 3 false false false false false false false true false false false true true true true true true false true false X X Carly Gilbert 9728610415 PO Box 1228 Red Oak TX 75154 Carly Gilbert VP / Treasurer 8.00 0.00 X X 15000 0 0 Clayton Greene Secretary 3.00 0.00 X X 0 0 0 Keith Massey Director 40.00 0.00 X 0 0 0 Chad Griffith President 8.00 0.00 X X 0 0 0 15000 0 false false false 0 70 380178 380248 0 0 0 291 291 0 0 0 0 0 0 380539 291 34596 34596 0 190675 190675 0 13438 1613 9406 2419 0 0 0 0 3130 376 2191 563 0 0 0 0 0 0 3001 106 2736 159 2248 1353 895 4321 3427 279 615 630 630 0 0 0 0 0 0 0 0 0 Study supplies and shipping 5926 5926 Dues and subscriptions 173 123 50 0 258138 236719 16718 4701 974230 1097526 0 0 0 0 0 0 895 0 0 0 0 0 0 0 0 975125 1097526 0 0 X 975125 1097526 975125 1097526 975125 1097526 122401 X false false false X 223484 257468 337166 378086 380248 1576452 0 0 223484 257468 337166 378086 380248 1576452 42834 1533618 165 282 348 378 291 1464 0 0 1577916 1011 0.97190 0.98240 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED true Europe 0 0 Grants to foreign recipients Medical research grant 120000 North America 0 0 Grants to foreign recipients Medical research grant 18685 E. Asia/Pacific 0 0 Grants to foreign recipients Medical research grant 51990 190675 190675 E. Asia/Pacific Medical research 51990 Wire Trfr Europe Medical research 120000 Wire Trfr North America Medical research 18685 Wire Trfr 3 false false false false false false Part I, Line 2 - Grantmakers Explanation For Monitoring Use of Funds Outside US Periodic reports, along with a detailed final report and analysis with findings, are required for each grant to account for how the grant funds are used. Future grant awards are contingent upon receipt of such reports to ensure that valuable resources are not wasted on research that is not beneficial. Part I, Line 3f - Method of Accounting The expenditures are reported using the cash basis of accounting. Part I, Line 3f - Investments and Expenditures All expenditures consists of research grants awarded to established institutions. Part II, Line 1 - Method of Accounting The expenditures are reported using the cash basis of accounting. true The Jackson Laboratory 600 Main St Bar Harbor ME 04609 010211513 501(c)(3) 34596 0 Medical research 1 0 Grantmaker's Description of How Grants are Used Periodic reports, along with a detailed final report and analysis with findings, are required for each grant to account for how the grant funds are used. Future grant awards are contingent upon receipt of such reports to ensure that valuable resources are not wasted on research that is not beneficial. Form 990, Part VI, Section A, Line 8b There are no such committees. Form 990, Part VI, Section B, Line 11b A copy of this return was provided to the Organization's President and Treasurer, who in turn forwarded it via email to all Directors for review and approval before filing. Form 990, Part VI, Section B, Line 12c Any director, principal officer, or member of a committee with governing boarddelegated powers, who has a direct or indirect financial interest, as defined below, is an interested person. In connection with any actual or possible conflict of interest, an interested person must disclose the existence of the financial interest and be given the opportunity to disclose all material facts to the directors and members of committees with governing board delegated powers considering the proposedtransaction or arrangement (and annual disclosure statements must be signed annually, and periodic reviews shall be conducted). After any discussion with the interested person, he/she shall leave the governing board or committee meeting while the determination of a conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. Conflict of interest is discussed and voted upon. The remaining board or committee members shall decide if a conflict of interest exists. In this case, the interesed person may make a presentation at the governing board or committee meeting, but after the presentation, he/she shall leave the meeting during the discussion of, and the vote on, the transaction or arrangement involving the possible conflict of interest. The chairperson of the governing board or committee shall, if appropriate, appoint a disinterested person or committee to investigate alternatives to the proposed transaction or arrangement. After exercising due diligence, the governing board or committee shall determine whether the Organization can obtain, with reasonable efforts, a more advantageous transaction or arrangement from a person or entity that would not give rise to a conflict of interest. If a more advantageous transaction or arrangement isnt reasonably possible under circumstances not producing a conflict of interest, the governing board or committee shall determine by a majority vote of the disinterested directors whether the transaction or arrangement is in the Organizations best interest, for its own benefit, and whether it is fair and reasonable. In conformity with the above determination, it shall make its decision as to whether to enter into the transaction or arrangement. Form 990, Part VI, Section B, Line 15b The Organization's top management official was not compensated during the year, but compensation of the VP / Treasurer was determined and approved by a majority of independent Directors after considering comparability data reported by National Council of Nonprofits and GuideStar, as documented in the minutes. Form 990, Part VI, Section C, Line 19 These documents are available on the Organization's website and upon request.